Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Dyadic International News

    1,49 $ 0,00% +0,00 $
    In : 1,3869 € | 25.04.24 22:00:04 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0JK0A
    ISIN: US26745T1016
    US-Symbol: DYAI
    Typ: Aktie

    Dyadic International News

    17.12.21 - GlobeNewswire
    Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform
    JUPITER, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on ...
    12.08.21 - ACCESSWIRE
    Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
    Executed binding term sheet with Sorrento Therapeutics (Nasdaq:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, ...
    11.08.21 - PR Newswire
    Thinking about buying stock in Dyadic Int, Seanergy Maritime, Cleveland-Cliffs, United States Steel, or Lightning Emotors?
    Thinking about buying stock in Dyadic Int, Seanergy Maritime, Cleveland-​Cliffs, United States Steel, or Lightning Emotors? PR Newswire
    29.07.21 - ACCESSWIRE
    Dyadic to Report Second Quarter 2021 Financial Results
    JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on ...
    27.07.21 - PR Newswire
    Thinking about buying stock in Tyme Technologies, New Oriental Education, Dyadic International, KE Holdings, or Iterum Therapeutics?
    Thinking about buying stock in Tyme Technologies, New Oriental Education, Dyadic International, KE Holdings, or Iterum Therapeutics? PR Newswire
    24.05.21 - ACCESSWIRE
    Dyadic to Present at Upcoming Events
    JUPITER, FL / ACCESSWIRE / May 24, 2021 /  Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving, ...
    13.05.21 - ACCESSWIRE
    Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
    Advancing Dyadic 's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-​in-human Phase 1 clinical trial Goal of validating that C1 produced proteins are safe in ...
    29.04.21 - ACCESSWIRE
    Dyadic to Report First Quarter 2021 Financial Results
    JUPITER, FL / ACCESSWIRE / April 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on ...
    26.04.21 - GlobeNewswire
    Dyadic International veranstaltet Kamingespräch mit dem Titel „The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges“
    Das Kamingespräch findet am Dienstag, den 4. Mai 2021, um 16 Uhr CEST statt
    22.04.21 - GlobeNewswire
    Dyadic International Hosting a Fireside Chat on “The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges”
    Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time
    30.03.21 - ACCESSWIRE
    Dyadic Reports 2020 Year End Results and Recent Company Progress
    Advancing Dyadic ' s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-​in-human Phase 1 clinical trial To validate C1 produced proteins are safe in humans and ...
    24.03.21 - GlobeNewswire
    Dyadic und Medytox entwickeln Impfstoffe gegen COVID-19-Varianten
    Ausweitung der seit Juli 2020 bestehenden Zusammenarbeit im Bereich der COVID-19-Impfstoffforschung Medytox und Dyadic entwickeln gemeinsam COVID-19-Impfstoffe ...
    23.03.21 - GlobeNewswire
    Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
    Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to co-​develop C1 enabled COVID-19 vaccines and/or boosters which will ...
    22.03.21 - PR Newswire
    Thinking about buying stock in Support.com, Seneca Biopharma, Hall of Fame Resort & Entertainment, Dyadic International, or Stonemor?
    Thinking about buying stock in Support.com, Seneca Biopharma, Hall of Fame Resort & Entertainment, Dyadic International, or Stonemor? PR Newswire
    16.03.21 - ACCESSWIRE
    Dyadic to Report Fourth Quarter and Full Year 2020 Financial Results
    JUPITER, FL / ACCESSWIRE / March 16, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on ...
    15.02.21 - ACCESSWIRE
    Dyadic to Present at Upcoming Events
    JUPITER, FL / ACCESSWIRE / February 15, 2021 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further ...
    03.02.21 - ACCESSWIRE
    Dyadic to Present at ZAPI Stakeholders Virtual Meeting
    JUPITER, FL / ACCESSWIRE / February 3, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its ...
    02.02.21 - ACCESSWIRE
    Dyadic Enters Collaboration with TurtleTree Scientific to Develop Recombinant Protein Growth Factors
    JUPITER, FL / ACCESSWIRE / February 2, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its ...
    11.01.21 - ACCESSWIRE
    Dyadic International Appoints New Board Member
    JUPITER, FL / ACCESSWIRE / January 11, 2021 /  Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its ...
    09.12.20 - ACCESSWIRE
    Dyadic to Interview with FOX Business Network on Wednesday December 9, 2020
    JUPITER, FL / ACCESSWIRE / December 9, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further ...

    Newssuche

    Videos

    newspaper
    08:40 Uhr +22,09%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »